GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Century Therapeutics Inc (NAS:IPSC) » Definitions » Gross Margin %

Century Therapeutics (Century Therapeutics) Gross Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Century Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Century Therapeutics's Gross Profit for the three months ended in Mar. 2024 was $0.86 Mil. Century Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.86 Mil. Therefore, Century Therapeutics's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Century Therapeutics's Gross Margin % or its related term are showing as below:


IPSC's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.43
* Ranked among companies with meaningful Gross Margin % only.

Century Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Century Therapeutics was 0.00% per year.


Century Therapeutics Gross Margin % Historical Data

The historical data trend for Century Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Century Therapeutics Gross Margin % Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
- - - - -

Century Therapeutics Quarterly Data
Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Century Therapeutics's Gross Margin %

For the Biotechnology subindustry, Century Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Century Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Century Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's Gross Margin % falls into.



Century Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Century Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=2.2 / 2.235
=(Revenue - Cost of Goods Sold) / Revenue
=(2.235 - 0) / 2.235
=N/A %

Century Therapeutics's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0.9 / 0.855
=(Revenue - Cost of Goods Sold) / Revenue
=(0.855 - 0) / 0.855
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Century Therapeutics  (NAS:IPSC) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Century Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Century Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Century Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Century Therapeutics (Century Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3675 Market Street, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
Executives
Luis Borges officer: Chief Scientific Officer TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Daphne Quimi director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Joseph Jimenez director ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Rizzuto Carlo director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Alessandro Riva director C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Hyam Levitsky officer: President of R&D C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Adrienne Farid officer: Chief Operations Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Gregory Russotti officer: Chief Technology Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Osvaldo Flores officer: Chief Executive Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Douglas Carr officer: VP of Finance and Operations C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104